Bank of Montreal Can Makes New $415,000 Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Bank of Montreal Can purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 35,586 shares of the company's stock, valued at approximately $415,000.

A number of other hedge funds have also modified their holdings of the stock. Regeneron Pharmaceuticals Inc. purchased a new position in Intellia Therapeutics in the fourth quarter valued at about $43,177,000. Contrarius Group Holdings Ltd acquired a new stake in shares of Intellia Therapeutics during the 4th quarter valued at about $11,798,000. Trexquant Investment LP bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $7,785,000. Vanguard Group Inc. grew its stake in shares of Intellia Therapeutics by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock valued at $118,816,000 after buying an additional 562,249 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $4,793,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Up 2.0 %

Shares of NTLA stock traded up $0.17 during trading hours on Monday, reaching $8.48. 3,140,582 shares of the company's stock were exchanged, compared to its average volume of 2,388,955. The business has a fifty day moving average price of $8.59 and a 200-day moving average price of $11.70. The stock has a market capitalization of $877.82 million, a P/E ratio of -1.56 and a beta of 2.23. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NTLA shares. The Goldman Sachs Group reissued a "sell" rating and issued a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th. Citigroup boosted their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a research note on Friday, February 28th. Wedbush reissued a "neutral" rating and issued a $10.00 price target (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Finally, Oppenheimer lowered their price target on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research note on Monday, January 13th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.68.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.